Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Pernas, S; Martin, M; Kaufman, PA; Gil-Martin, M; Pardo, PG; Lopez-Tarruella, S; Manso, L; Ciruelos, E; Perez-Fidalgo, JA; Hernando, C; Ademuyiwa, FO; Weilbaecher, K; Mayer, I; Pluard, TJ; Garcia, MM; Vahdat, L; Perez-Garcia, J; Wach, A; Barker, D; Fung, S; Romagnoli, B; Cortes, J.

Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial

LANCET ONCOLOGY. 2018; 19(6): 812-824 Nº de citas: 125 [doi:10.1016/S1470-2045(18)30147-5]

Santonja A; Sanchez-Munoz A; Lluch A; Chica-Parrado MR; Albanell J; Chacon JI; Antolin S; Jerez JM; de la Haba J; de Luque V; Fernandez-De Sousa CE; Vicioso L; Plata Y; Ramirez-Tortosa CL; Alvarez M; Llacer C; Zarcos-Pedrinaci I; Carrasco E; Caballero R; Martin M; Alba E.

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy.

Oncotarget. 2018; 9(41): 26406-26416 Nº de citas: 154 [doi:10.18632/oncotarget.25413]

Hill, AG; Findlay, MP; Burge, ME; Jackson, C; Alfonso, PG; Samuel, L; Ganju, V; Karthaus, M; Amatu, A; Jeffery, M; Di Bartolomeo, M; Bridgewater, J; Coveler, AL; Hidalgo, M; Kapp, AV; Sufan, RI; McCall, BB; Hanley, WD; Penuel, EM; Pirzkall, A; Tabernero, J.

Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer

CLINICAL CANCER RESEARCH. 2018; 24(10): 2276-2284 Nº de citas: 53 [doi:10.1158/1078-0432.CCR-17-0646]

Alfonso, PG; Podesta, MC; Martin, AM; Codeisido, MB; Calvo, A; Peligros, I; Corcuera, A; Blanco, ABR; Custodio-Cabello, S; Trabada, DL; Martin, M; De Ramon, E.

Chemotherapy Plus Bevacizumab as Neoadjuvant or Conversion Treatment in Patients with Colorectal Liver Metastases

ANTICANCER RESEARCH. 2018; 38(5): 3069-3077 Nº de citas: 4 [doi:10.21873/anticanres.12564]

Visa, L; Jimenez-Fonseca, P; Martinez, EA; Hernandez, R; Custodio, A; Garrido, M; Viudez, A; Buxo, E; Echavarria, I; Cano, JM; Macias, I; Mangas, M; de Castro, EM; Garcia, T; Mancenido, FA; Montes, AF; Azkarate, A; Longo, F; Serrano, AD; Lopez, C; Hurtado, A; Cerda, P; Serrano, R; Gil-Negrete, A; Carnicero, AM; Pimentel, P; Ramchandani, A; Carmona-Bayonas, A; AGAMENON Study Grp.

Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer:. A real-world data, non-inferiority analysis

Journal of Geriatric Oncology. 2018; 9(3): 254-264 Nº de citas: 14 [doi:10.1016/j.jgo.2017.11.008]

Martin, M; Campone, M; Bondarenko, I; Sakaeva, D; Krishnamurthy, S; Roman, L; Lebedeva, L; Vedovato, JC; Aapro, M.

Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane

ANNALS OF ONCOLOGY. 2018; 29(5): 1195-1202 Nº de citas: 13 [doi:10.1093/annonc/mdy063]

Alvarez, R; Carrato, A; Adeva, J; Ales, I; Prados, S; Valladares, M; Macarulla, T; Munoz, A; Hidalgo, M.

Management of hyperbilirubinaemia in pancreatic cancer patients

EUROPEAN JOURNAL OF CANCER. 2018; 94: 26-36 Nº de citas: 11 [doi:10.1016/j.ejca.2018.01.078]

Ethier, JL; Ocana, A; Lescure, AR; Ruiz, A; Alba, E; Calvo, L; Ruiz-Borrego, M; Santaballa, A; Rodriguez, CA; Crespo, C; Ramos, M; Marco, JG; Lluch, A; Alvarez, I; Casas, M; Sanchez-Arago, M; Carrasco, E; Caballero, R; Amir, E; Martin, M.

Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study

EUROPEAN JOURNAL OF CANCER. 2018; 94: 199-205 Nº de citas: 21 [doi:10.1016/j.ejca.2018.02.018]

Echavarria, I; Lopez-Tarruella, S; Picornell, A; Garcia-Saenz, JA; Jerez, Y; Hoadley, K; Gomez, HL; Moreno, F; Del Monte-Millan, M; Marquez-Rodas, I; Alvarez, E; Ramos-Medina, R; Gayarre, J; Massarrah, T; Ocana, I; Cebollero, M; Fuentes, H; Barnadas, A; Ballesteros, AI; Bohn, U; Perou, CM; Martin, M.

Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification

CLINICAL CANCER RESEARCH. 2018; 24(8): 1845-1852 Nº de citas: 94 [doi:10.1158/1078-0432.CCR-17-1912]

Wapnir, IL; Price, KN; Anderson, SJ; Robidoux, A; Martin, M; Nortier, JWR; Paterson, AHG; Rimawi, MF; Lang, I; Baena-Canada, JM; Thurlimann, B; Mamounas, EP; Geyer, CE; Gelber, S; Coates, AS; Gelber, RD; Rastogi, P; Regan, MM; Wolmark, N; Aebi, S; NRG Oncology; GEICAM Spanish Breast Canc Grp; BOOG Dutch Breast Canc Trialists G; Breast Int Grp.

Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial

JOURNAL OF CLINICAL ONCOLOGY. 2018; 36(11): 1073-1079 Nº de citas: 107 [doi:10.1200/JCO.2017.76.5719]

Palacios Calvo J; Albanell J; Rojo F; Ciruelos E; Aranda-Lopez I; Cortes J; Garcia-Caballero T; Martin M; Lopez-Garcia MA; Colomer R.

Consenso de la Sociedad Espanola de Anatomia Patologica y la Sociedad Espanola de Oncologia Medica sobre biomarcadores en cancer de mama.

Revista Espanola de Patologia. 2018; 51(2): 97-109 Nº de citas: 2 [doi:10.1016/j.patol.2017.12.002]

Garrido, P; Aldaz, A; Vera, R; Calleja, MA; de Alava, E; Martin, M; Matias-Guiu, X; Palacios, J.

Proposal for the creation of a national strategy for precision medicine in cancer: a position statement of SEOM, SEAP, and SEFH

Clinical & Translational Oncology. 2018; 20(4): 443-447 Nº de citas: 18 [doi:10.1007/s12094-017-1740-0]

Di Leo, A; Jerusalem, G; Torres, R; Verhoeven, D; Pendergrass, K; Malorni, L; Lichfield, J; Martin, M.

First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study

BREAST. 2018; 38: 144-149 Nº de citas: 12 [doi:10.1016/j.breast.2017.12.016]

Hanna, GJ; Busaidy, NL; Chau, NG; Wirth, LJ; Barletta, JA; Calles, A; Haddad, RI; Kraft, S; Cabanillas, ME; Rabinowits, G; O'Neill, A; Limaye, SA; Alexander, EK; Moore, FD; Misiwkeiwicz, K; Thomas, T; Nehs, M; Marqusee, E; Lee, SL; Janne, PA; Lorch, JH.

Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study

CLINICAL CANCER RESEARCH. 2018; 24(7): 1546-1553 Nº de citas: 100 [doi:10.1158/1078-0432.CCR-17-2297]

Martin, AJM; Ortega, I; Font, C; Pachon, V; Castellon, V; Martinez-Marin, V; Salgado, M; Martinez, E; Calzas, J; Ruperez, A; Souto, JC; Martin, M; Salas, E; Soria, JM.

Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer

BRITISH JOURNAL OF CANCER. 2018; 118(8): 1056-1061 Nº de citas: 106 [doi:10.1038/s41416-018-0027-8]

Calvo-Ferrandiz, E; Peraita-Adrados, R.

Narcolepsy with cataplexy and pregnancy: a case-control study

JOURNAL OF SLEEP RESEARCH. 2018; 27(2): 268-272 Nº de citas: 22 [doi:10.1111/jsr.12567]

Rugo, HS; Dieras, V; Gelmon, KA; Finn, RS; Slamon, DJ; Martin, M; Neven, P; Shparyk, Y; Mori, A; Lu, DR; Bhattacharyya, H; Bartlett, CH; Iyer, S; Johnston, S; Ettl, J; Harbeck, N.

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial

ANNALS OF ONCOLOGY. 2018; 29(4): 888-894 Nº de citas: 129 [doi:10.1093/annonc/mdy012]

Samaniego, R; Gutierrez-Gonzalez, A; Gutierrez-Seijo, A; Sanchez-Gregorio, S; Garcia-Gimenez, J; Mercader, E; Marquez-Rodas, I; Aviles, JA; Relloso, M; Sanchez-Mateos, P.

CCL20 Expression by Tumor-Associated Macrophages Predicts Progression of Human Primary Cutaneous Melanoma

Cancer Immunology Research. 2018; 6(3): 267-275 Nº de citas: 66 [doi:10.1158/2326-6066.CIR-17-0198]